Director, Bioconjugation
Core
Lead strategic direction for bioconjugation across antibody-drug conjugate (ADC) and antibody–RNA conjugate (ARC/AOC) portfolios, setting chemistry selection, site-specificity, and DAR distribution while partnering with Chemistry on linker–payload design.
Role type
Director, Bioconjugation (Scientific Leadership)
Builds
Discovery-stage antibody-based conjugate candidates (small molecule cytotoxic, oligonucleotide, targeted protein degrader, dual-payload formats)
Domain
Biopharmaceuticals / Antibody-Drug Conjugates (ADC) / Antibody-RNA Conjugates (ARC)
Deliverable
production ML models | product features | dashboards & analysis | research | client delivery | infrastructure | physical/clinical work
Required skills
Bioconjugation chemistry (cysteine/lysine, site-specific, enzymatic, click/bioorthogonal), Linker design, ADC program leadership, Analytical data interpretation (RP-HPLC, SEC, LC-MS/HRMS), Stakeholder influence
Preferred skills
Oligonucleotide therapeutics expertise, Glycan-mediated bioconjugation, Targeted protein degradation, Dual-payload design, CMC/tech-transfer, High-throughput/automated conjugation, Computational/ML-guided design
Technologies
RP-HPLC, SEC, HIC, IEX, LC-MS/HRMS, CE-SDS
Responsibilities
Lead bioconjugation team and set scientific direction; Define enterprise bioconjugation strategy (chemistry selection, site-specificity, DAR); Act as lead on discovery program teams for conjugate design; Partner with Global Chemistry, Biologics, and Translational Sciences; Represent bioconjugation at governance reviews; Champion data standardization and computational design approaches
Seniority
Director, Strategic Leadership
